top of page

CHILDREN WITH AUTISM
SPECTRUM DISORDERS (ASD)

Pilot Study

shutterstock_1463202677 1 (1).png
OUR ADVISORS
Frame 36 (1).png
STEPHANY COX, PHD

Autism Advisor

Pediatric Neuropsychologist, UCSF

Tamar-Maritz-e1568279697515.jpg
TAMAR MARITZ, MBA

CA Cannabis Market Advisor

VP Business Development, BDS Analytics

wpa4a_logo_transparent_bg.png
Canniatric_Horizontal_colour_RGB_300dpi.
OUR VALUED SPONSORS
BonniGoldstein.png
BONNI GOLDSTEIN, MD

Clinical Advisor

Canna Center LOGO.png
shutterstock_1221615613 [Converted]-01 (

METHODOLOGY

shutterstock_429937732 [Converted]-02.pn

1

PARTICIPANTS
  • Children diagnosed with ASD.

  • Currently using medical cannabis under HCP supervision.

  • Living in California (Los Angeles and San Francisco Bay Area).

PRIVACY
  • Children’s data privacy is protected by HIPAA-compliant protocols.

shutterstock_429937732 [Converted]-03.pn

2

Cannformatics-HeroBanner-04.png

3

SAMPLES
  • ASD: Saliva collected from children pre- and post-consumption of regularly prescribed medical cannabis dosage. 

  • Control: Saliva collected from age-matched neurotypical children.

ANALYSIS
  • Cannformatics’ proprietary platform identifies biomarkers that significantly changed pre- and post-consumption of medical cannabis.

  • Samples from neurotypical children are collected and analyzed to determine the biomarkers  baseline for healthy physiological range.

shutterstock_429937732 [Converted]-07.pn

4

shutterstock_429937732 [Converted]-07.pn

5

REPORTS
  • Study participants will receive a report showing their individual changes in biomarkers related to ASD symptoms before and after medical cannabis consumption.

  • We will seek to publish the finding in a scientific peer-reviewed medical journal, across mainstream media and at Cannformatics.com.

web2-01.jpg
Frame 1 (8) (1).png

OUR GOAL

To be a trusted resource for parents and health care professionals by providing data and insights to build an effective cannabis regimen for children with ASD.

bottom of page